Clinical Trial Update: VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2 [Phase 4]

View source ↗

Summary

A Phase 4 trial assessed once-daily valacyclovir (Valtrex) for reducing HSV-2 viral shedding in individuals newly diagnosed with genital herpes; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes
• Herpes Labialis

Drugs mentioned

• VALTREX (valacyclovir hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Labialis | Phase 4 | Status: COMPLETED | Results posted: 2018-03-23